New drug cocktail aims to fight cervical cancer without chemo

NCT ID NCT04906993

Ongoing Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tests whether a combination of two drugs, camrelizumab and famitinib, works better than standard chemotherapy for women with recurrent or metastatic cervical cancer. About 443 participants will be randomly assigned to receive either the drug combo or chemo. The study measures how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab and famitinib malate
What this could lead to: If successful, this combination could provide a new treatment option for people with recurrent or metastatic cervical cancer, potentially improving survival without the need for chemotherapy.
What could go wrong: This is a Phase 3 trial, but results are not yet available. The combination may not prove better than chemotherapy, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical squamous cell carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.